Lung adenocarcinoma
Conditions
Interventions
None listed
Sponsors
University of Miyazaki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with lung adenocarcinoma 1.Patients aged equal to or greater than 20 years-old. 2.Patients who have single lung lesion in high resolution CT (in patients who need lung cancer surgery) 3.Patients who have no findings of metastatic lesions in brain MRI or CT, thoracoabdominal CT, bone scintigraphy or FDG-PET (in patients who need lung cancer surgery) ) 4. Patients diagnosed lung adenocarcinoma by surgical pathology(WHO Classification of Tumors of The Lung, Pleura, Thymus and Heart 4th edition), cytology or histopathology 5. Patients who had a detailed briefing of the trial prior to the enrollment and voluntarily signed a consent form Ptients with COPD 1.Patients aged equal to or greater than 40 years-old. 2. postbronchodilator FEV1/FVC (forced expiratory volume in 1s/forced vital capacity) < 0.70 assessed by spirometry and current smokers or ex-smokers 3. Patients who had a detailed briefing of the trial prior to the enrollment and voluntarily signed a consent form Healthy controls 1.Those who are equal to or greater than 20 years-old at the time of obtaining informed consent. 2.Those who have no abnormal findings in chest X-ray, blood glucose levels, serum lipids, serum liver function, serum renal function, and urinalysis within one year of obtaining informed consent. 3.Those who do not receive any regular prescriptions. 4.Those who are never smokers. 5.Those who had a detailed briefing of the trial prior to the enrollment and voluntarily signed a consent form
Exclusion criteria
Exclusion criteria: Patients with lung adenocarcinoma 1.Patients who received treatment for lung adenocarcinoma 2. Patients who have proteinuria, positive urine sugar or urine occult blood in urinalysis. 3.Patients who have renal dysfunction (Serum levels of creatinine > 2.0 mg/dl). 4.Patients who have current malignant neoplasm other than lung adenocarcinoma, or past history of malignant neoplasm within 5 years. 5.patients who were diagnosed with other types of lung cancer (not lung adenocarcinoma) 6.Patients who have alcohol or drug dependence or who are suspected to have alcohol or drug dependence. 7.Patients who is pregnant or who is suspected to be pregnant. 8.Patients who was enrolled another clinical trial and was prescribed a study drug within one month. 9.Patients whose attending physicians consider to be inappropriate for this study. Patients with COPD 1.Patients who have proteinuria, positive urine sugar or urine occult blood in urinalysis. 2.Patients who have current malignant neoplasm other than lung squamous cell carcinoma, or past history of malignant neoplasm within 5 years. 3.Patients who have alcohol or drug dependence or who are suspected to have alcohol or drug dependence. 4.Patients who is pregnant or who is suspected to be pregnant. 5.Patients who was enrolled another clinical trial and was prescribed a study drug within one month. 6.Patients who were clinicaly suspected lung cancer by high resolution CT within 3 months. 7.Patients who have renal dysfunction (Serum levels of creatinine > 2.0 mg/dl). 8.Patients whose attending physicians consider to be inappropriate for this study. Healthy controls 1-5. Same criterias as COPD (1-5.) 6.Those who are current smokers or ex-smokers. 7.Those whose attending physicians consider to be inappropriate for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diagnostic accuracy of the urinary protein fragment for lung adenocarcinoma. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Comparison of diagnostic accuracy of urinary protein fragment and Carcinoembryonic antigen(CEA) for lung adenocarcinoma 2. Comparison of diagnostic accuracy of urinary protein fragment and CEA for early-stage (Stage I) lung adenocarcinoma 3. Diagnostic accuracy of combination marker (urinary protein fragment and CEA) 4. Changes in urine level of protein fragment before and after surgery 5. Comparison of urinary level of the protein fragment between early stage (Stage 1) lung adenocarcinoma and advance stage (Stage 2, 3 and 4) lung adenocarcinoma 6. Expression level of the protein fragment or the original protein in blood and lung tissue 7. Relationship between urinary level of protein fragment and KRAS mutation and between expression level of original protein and KRAS mutation 8. Relationship between the expression levels of cancer stem cell markers and urinary level of protein fragment, between the expression levels of EMT related genes in cancer tissue and urinary level of protein fragment,and between vascular invasion in cancer tissue and urinary levels of protein fragments | — |
Countries
Japan
Contacts
Public ContactHironobu Tsubouchi
University of Miyazaki Neurology, Respirology, Endocrinology and Metabolism, Internal Medicine, Faculty of Medicine
Outcome results
None listed